Document:

Unassociated Document

    ESCROW
      DEPOSIT AGREEMENT

    

    AGREEMENT
      dated
      this ____ day of [ ______ ] 2007, by and among RxElite
      Holdings, Inc.,
      a
      Delaware corporation (the “Company”),
      having an address at 1404 N. Main Street, Suite 200, Meridian, Idaho 83642,
      [___________] (the “Investor
      Representative”)
      and
SIGNATURE
      BANK (the
      “Escrow
      Agent”),
      a New
      York State chartered bank, having an office at 300 Park Avenue, New York, New
      York 10022.

     

    WITNESSETH:
      

    

    WHEREAS,
      the
      Company is offering (the “Offering”)
      a
      minimum of $5,000,000 (the “Minimum
      Amount”)
      of the
      Company’s units (the “Units”),
      each
      Unit consisting of one share of the Company’s common stock, par value $0.00237
      per share (the “Common
      Stock”)
      and a
      detachable warrant to purchase 1⁄2 of one share of Common Stock at an exercise
      price of $0.85 per share;

     

    WHEREAS,
      unless
      the Offering is completed by ________, 2007 (the “Termination
      Date”),
      unless extended by the Company and the Investor Representative for up at an
      additional 1-week period (the “Final
      Termination Date”),
      the
      Offering will terminate and all funds will be returned to the subscribers in
      the
      Offering (the “Subscribers”)
      without interest, penalty or offset;

     

    WHEREAS,
      immediately prior to the initial closing of the Offering, Subscribers will
      be
      provided a draft Current Report on Form 8-K (the “Form
      8-K”),
      and
      in connection therewith Subscribers will be asked to execute a reconfirmation
      of
      their desire to subscribe for the Units in the Offering;

     

    WHEREAS,
      the
      Company desires to establish an escrow account with the Escrow Agent into which
      the Company shall instruct the Subscribers to deposit checks and other
      instruments or wire funds for the payment of money made payable to the order
      of
“Signature Bank, as Escrow Agent for RxElite Holdings, Inc.,” and Escrow Agent
      is willing to accept said checks and other instruments and wires for the payment
      of money in accordance with the terms hereinafter set forth;

     

    WHEREAS,
      the
      Company represents and warrants to the Escrow Agent that it has not stated
      to
      any individual or entity that the Escrow Agent’s duties will include anything
      other than those duties stated in this Agreement; and

     

    WHEREAS,
      the
      Company represents and warrants to the Escrow Agent that a copy of all documents
      that have been delivered to Subscribers and third parties that include Escrow
      Agent’s name and duties, have been attached hereto as Schedule I.

     

    NOW,
      THEREFORE, IT IS AGREED as
      follows:

     

    1. Delivery
      of Escrow Funds.

     

    (a) The
      Company shall instruct Subscribers to deliver to Escrow Agent checks made
      payable to the order of “Signature Bank, as Escrow Agent for RxElite Holdings,
      Inc.”, or wire transfer to [___________] for credit to Signature Bank, as Escrow
      Agent for RxElite Holdings, Inc., Account No. _____________, in each case,
      with
      the name, address and social security number or taxpayer identification number
      of the individual or entity making payment. In the event any Subscriber’s
      address and/or social security number or taxpayer identification number are
      not
      provided to Escrow Agent by the Subscriber, then the Company and the Investor
      Representative agree to promptly provide Escrow Agent with such information
      (unless the Subscriber is a non-U.S. person). The checks or wire transfers
      shall
      be deposited into a non-interest-bearing account at Signature Bank entitled
      “Signature Bank, as Escrow Agent for RxElite Holdings, Inc.” (the “Escrow
      Account”).

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) The
      collected funds deposited into the Escrow Account are referred to as the
“Escrow
      Funds.”

     

    (c) Escrow
      Agent shall have no duty or responsibility to enforce the collection or demand
      payment of any funds deposited into the Escrow Account. If, for any reason,
      any
      check deposited into Escrow Account shall be returned unpaid to the Escrow
      Agent, the sole duty of the Escrow Agent shall be to return the check to the
      Subscriber and advise the Company promptly thereof.

     

    (d) Escrow
      Agent shall hold all Escrow Funds in the Escrow Account free from any lien,
      claim or offset of Escrow Agent, except as set forth herein.

     

    2. Release
      of Escrow Funds.
      The
      Escrow Funds shall be paid by the Escrow Agent in accordance with the
      following:

     

    (a) In
      the
      event that the Company and the Investor Representative advise Escrow Agent
      in
      writing that the Offering has been terminated (the “Termination
      Notice”),
      Escrow Agent shall promptly return the funds paid by each Subscriber to said
      Subscriber without interest or deduction, penalty or expense.

     

    (b) If
      prior
      to 3:00 P.M. (local New York City time) on the Termination Date, Escrow Agent
      receives written notification, in the form of Exhibit A, attached hereto and
      made a part hereof, and signed by the Company and the Investor Representative,
      stating that the Termination Date has been extended, the date shall be so
      extended to the Final Termination Date.

     

    (c) Provided
      that the Escrow Agent does not receive the Termination Notice stated in
      paragraph 2(a) above and there is the Minimum Amount deposited into the Escrow
      Account on or prior to the end of the Termination Date or the Final Termination
      Date (if Escrow Agent has, prior to the Termination Date, received Exhibit
      A in
      accordance with paragraph 2(b) above), Escrow Agent shall, upon receipt of
      written instructions, in form and substance satisfactory to Escrow Agent,
      received from the Company and the Investor Representative (including a
      representation from the Company that the Company has furnished each Subscriber
      with the Form 8-K and that each Subscriber reconfirmed its investment in the
      Offering following receipt of the Form 8-K), pay the Escrow Funds in accordance
      with such written instructions, such payment or payments to be made by wire
      transfer within one (1) business day of receipt of such written instructions.
      The same procedures shall be coordinated with respect to any subsequent closings
      occurring prior to the Termination Date (if Escrow Agent has, prior to the
      Termination Date, received Exhibit A in accordance with paragraph 2(b)
      above).

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    (d) If
      by
      3:00 P.M. (local New York City time) on the later of the Termination Date or
      the
      Final Termination Date (if Escrow Agent has received Exhibit A, in accordance
      with paragraph 2(b) above), Escrow Agent (i) has not received written
      instructions from the Company and the Investor Representative and wire transfer
      instructions executed by the Company and the Investor Representative regarding
      the disbursement of the Escrow Funds and payment of fees and expenses of the
      Offering, or (ii) there is a balance in Escrow Account of less than the Minimum
      Amount, the Escrow Agent shall promptly return the Escrow Funds to the
      Subscribers without interest or deductions, penalty or expense. The Escrow
      Funds
      returned to each Subscriber shall be free and clear of any and all claims of
      Escrow Agent.

     

    (e) Escrow
      Agent shall not be required to pay any uncollected funds or any funds which
      are
      not available for withdrawal.

     

    (f) If
      the
      Termination Date or any other date that is a deadline under this Agreement
      for
      giving Escrow Agent notice or instructions or for the Escrow Agent to take
      action is not a Banking Day, then such date shall be changed to the Banking
      Day
      that immediately precedes such date. A “Banking
      Day”
is
      any
      day other than a Saturday, Sunday or a day that a New York State chartered
      bank
      is not legally obligated to be opened.

     

    (g) The
      Company may reject or cancel any subscription in the Offering in whole or in
      part. If payment for any such rejected or canceled subscription has been
      delivered to Escrow Agent, the Company will inform Escrow Agent of the rejection
      or cancellation, and Escrow Agent upon receiving such notice shall promptly
      return such funds to said Subscriber, but in no event prior to those funds
      becoming collected and available for withdrawal. In addition, Subscribers are
      required to reconfirm their subscription upon receipt of the Form 8-K.
      Subscribers who do not reconfirm their subscription will be entitled to a return
      of their subscription funds, without interest or deduction, and Escrow Agent
      upon receiving written notice from the Company shall promptly return such funds
      to such Subscribers.

     

    (h) Notwithstanding
      anything to contrary that may be contained herein, any Subscribers may instruct
      Escrow Agent to return such Subscriber’s subscriptions at any time prior to a
      closing on such Subscriber’s funds in accordance with the terms set forth
      herein. Upon receipt of such an instruction, Escrow Agent shall promptly return
      such funds to said Subscriber.

     

    3. Acceptance
      by Escrow Agent.
      Escrow
      Agent hereby accepts and agrees to perform its obligations hereunder, provided
      that:

     

    (a) Escrow
      Agent may act in reliance upon any signature believed by it to be genuine,
      and
      may assume that any person who has been designated by the Company and any other
      person to give any written instructions, notice or receipt, or make any
      statements in connection with the provisions hereof has been duly authorized
      to
      do so. Escrow Agent shall have no duty to make inquiry as to the genuineness,
      accuracy or validity of any statements or instructions or any signatures on
      statements or instructions. The names and true signatures of each individual
      authorized to act singly on behalf of the Company and other persons are stated
      in Schedule II, which is attached hereto and made a part hereof. The Company
      and
      each other person may each remove or add one or more of its authorized signers
      stated on Schedule II by notifying the Escrow Agent of such change in accordance
      with this Agreement, which notice shall include the true signature for any
      new
      authorized signatories.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (b) Escrow
      Agent may act relative hereto in reliance upon advice of counsel in reference
      to
      any matter connected herewith. The Escrow Agent shall not be liable for any
      mistake of fact or error of judgment or law, or for any acts or omissions of
      any
      kind, unless caused by its willful misconduct or gross negligence.

     

    (c) The
      Company and the Investor Representative agree to indemnify and hold Escrow
      Agent
      harmless from and against any and all claims, losses, costs, liabilities,
      damages, suits, demands, judgments or expenses (including but not limited to
      reasonable attorney’s fees) claimed against or incurred by Escrow Agent, in good
      faith, arising out of or related, directly or indirectly, to this Escrow
      Agreement unless caused by a breach of this Escrow Agreement by Escrow Agent
      or
      by Escrow Agent’s gross negligence or willful misconduct.

     

    (d) In
      the
      event that Escrow Agent shall be uncertain as to its duties or rights hereunder,
      Escrow Agent shall be entitled to (i) refrain from taking any action other
      than
      to keep safely the Escrow Funds until it shall be directed otherwise by a court
      of competent jurisdiction, or (ii) deliver the Escrow Funds to a court of
      competent jurisdiction.

     

    (e) Escrow
      Agent shall have no duty, responsibility or obligation to interpret or enforce
      the terms of any agreement other than Escrow Agent’s obligations hereunder, and
      the Escrow Agent shall not be required to make a request that any monies be
      delivered to the Escrow Account, it being agreed that the sole duties and
      responsibilities of Escrow Agent, to the extent not prohibited by applicable
      law, shall be (i) to accept checks or other instruments for the payment of
      money
      and wire transfers delivered to Escrow Agent for the Escrow Account and deposit
      said checks and wire transfers into the non-interest bearing Escrow Account,
      and
      (ii) to disburse or refrain from disbursing the Escrow Funds as stated above,
      provided that the checks received by Escrow Agent have been collected and are
      available for withdrawal.

     

    4. Resignation
      and Termination of the Escrow Agent.
      Escrow
      Agent may resign at any time by giving 30 days’ prior written notice of such
      resignation to the Company and the Investor Representative. Upon providing
      such
      notice, Escrow Agent shall have no further obligation hereunder except to hold
      the Escrow Funds that it receives until the end of such 30-day period. In such
      event, Escrow Agent shall not take any action, other than receiving and
      depositing funds, until the Company and the Investor Representative have
      designated a banking corporation, trust company, attorney or other person as
      successor. Upon receipt of such written designation signed by the Company and
      the Investor Representative, the Escrow Agent shall promptly deliver the Escrow
      Funds to such successor and shall thereafter have no further obligations
      hereunder. If such instructions are not received within 30 days following the
      effective date of such resignation, then the Escrow Agent may deposit the Escrow
      Funds and any other amounts held by it pursuant to this Agreement with a clerk
      of a court of competent jurisdiction pending the appointment of a successor.
      In
      either case provided for in this paragraph, Escrow Agent shall be relieved
      of
      all further obligations and released from all liability thereafter arising
      with
      respect to the Escrow Funds.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    5. Termination.
      The
      Company and the Investor Representative may terminate the appointment of the
      Escrow Agent hereunder upon written notice specifying the date upon which such
      termination shall take effect, which date shall be at least 30 days from the
      date of such notice. In the event of such termination, the Company and the
      Investor Representative shall, within 30 days of such notice, appoint a
      successor escrow agent and the Escrow Agent shall, upon receipt of written
      instructions signed by the Company and the Investor Representative turn over
      to
      such successor escrow agent all of the Escrow Funds; provided, however, that
      if
      the Company and the Investor Representative fail to appoint a successor escrow
      agent within such 30-day period, such termination notice shall be null and
      void
      and Escrow Agent shall continue to be bound by all of the provisions hereof.
      Upon receipt of the Escrow Funds, the successor escrow agent shall become Escrow
      Agent hereunder and shall be bound by all of the provisions hereof and Signature
      Bank shall be relieved of all further obligations and released from all
      liability thereafter arising with respect to the Escrow Funds.

     

    6. Investment.
      All
      funds received by Escrow Agent will be held only in non-interest bearing bank
      accounts at Signature Bank.

     

    7. Compensation.
      Escrow
      Agent shall be entitled, for the duties to be performed by it hereunder, to
      a
      fee of $2,500 which fee shall be paid by the Company promptly following the
      signing of this Agreement. In addition, the Company shall be obligated to
      reimburse Escrow Agent for all costs and expenses incurred in good faith in
      connection with the Escrow Account and this Agreement, including reasonable
      counsel fees. Neither the modification, cancellation, termination or rescission
      of this Agreement, nor the resignation or termination of the Escrow Agent shall
      affect the right of Escrow Agent to retain the amount of any fee that has been
      paid, or be reimbursed or paid for any fees, costs or expenses that have been
      incurred or become due prior to the effective date of any such modification,
      cancellation, termination, resignation or rescission. To the extent Escrow
      Agent
      has incurred any such costs or expenses or any such fees become due prior to
      any
      closing, Escrow Agent shall advise the Company and the Investor Representative
      and the Company and the Investor Representative shall direct all such amounts
      to
      be paid directly at any such closing.

     

    8. Notices.
      All
      notices, requests, demands and other communications required or permitted to
      be
      given hereunder shall be in writing and shall be deemed to have been duly given
      if sent by hand-delivery, by facsimile (followed by first-class mail), by
      nationally recognized overnight courier service or by registered or certified
      mail, return receipt requested, in each case costs prepaid, to the addresses
      set
      forth below.

     

    If
      to the
      Company:

     

    RxElite
      Holdings Inc.

    1404
      N.
      Main Street, Suite 200

    Meridian,
      ID 83642

    Attention:
      Daniel Chen, Chief Executive Officer

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    

    If
      to the
      Investor Representative:

    _______________

    _______________

    _______________

    

    If
      to
      Escrow Agent:

     

    Signature
      Bank

    300
      Park
      Avenue

    New
      York,
      New York 10022

    Attention:
      Mr. Norman Lowe, Group Director and Senior Vice President

    

    9. General.

     

    (a) This
      Agreement shall be governed by and construed and enforced in accordance with
      the
      laws of the State of New York applicable to agreements made and to be entirely
      performed within such State without regard to choice of law
      principles.

     

    (b) This
      Agreement sets forth the entire agreement and understanding of the parties
      in
      respect to the matters contained herein and supersedes all prior agreements,
      arrangements and understandings relating thereto.

     

    (c) All
      of
      the terms and conditions of this Agreement shall be binding upon, and inure
      to
      the benefit of and be enforceable by, the parties hereto.

     

    (d) This
      Agreement may be amended, modified, superseded or canceled, and any of the
      terms
      or conditions hereof may be waived, only by a written instrument executed by
      each party hereto or, in the case of a waiver, by the party waiving compliance.
      The failure of any party at any time or times to require performance of any
      provision hereof shall in no manner affect its right at a later time to enforce
      the same. No waiver of any party of any condition, or of the breach of any
      term
      contained in this Agreement, whether by conduct or otherwise, in any one or
      more
      instances shall be deemed to be or construed as a further or continuing waiver
      of any such condition or breach or a waiver of any other condition or of the
      breach of any other term of this Agreement. No party may assign any rights,
      duties or obligations hereunder unless all other parties have given their prior
      written consent.

     

    (e) If
      any
      provision included in this Agreement proves to be invalid or unenforceable,
      it
      shall not affect the validity of the remaining provisions.

     

    (f) This
      Agreement and any amendment or modification of this Agreement may be executed
      in
      several counterparts or by separate instruments and all of such counterparts
      and
      instruments shall constitute one agreement, binding on all of the parties
      hereto.

     

    10. Form
      of Signature.
      The
      parties hereto agree to accept a facsimile transmission copy of their respective
      actual signatures as evidence of their actual signatures to this Agreement
      and
      any amendment or termination of this Agreement; provided, however, that each
      party who produces a facsimile signature agrees, by the express terms hereof,
      to
      place, promptly after transmission of his or her signature by fax, a true and
      correct original copy of his or her signature in overnight mail to the address
      of the other party.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    [SIGNATURE
      PAGE FOLLOWS] 

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF,
      the
      parties have duly executed this Agreement as of the date first set forth
      above. 

     

    
      	 	 	RXELITE HOLDINGS,
              INC.
	 	 	
               

              By:  

              
                

              

              Name: 

              
                

              

              Title:  

              
                
 

            
	 	 	
              INVESTOR
                REPRESENTATIVE

               

              By:  

              
                

              

              Name:  

              
                

              

              Title:  

              
                

              

               

            
	
              SIGNATURE
                BANK

               

              By:  

              
                

              

              Name:  

              
                

              

              Title:  

              
                

              

               

               

              By:  

              
                

              

              Name:  

              
                

              

              Title:  

              
                
 

            	 	 

    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    Date:
      __________________

    Signature
      Bank

    300
      Park
      Avenue

    New
      York,
      New York 10022

    Attention:
      Norman Lowe, Group Director and Senior Vice President

    

    Dear
      Mr.
      Lowe:

    

    In
      accordance with the terms of Section 2(b) of an Escrow Deposit Agreement dated
      __________, 2007, by and among RXELITE
      HOLDINGS, INC. (the
      “Company”),
      [            ] (the
“Investor Representative”) and SIGNATURE
      BANK (the
      “Escrow
      Agent”),
      the
      Company and the Investor Representative hereby notify the Escrow Agent that
      the
      Termination Date has been extended to __________ __, 2007.

     

    Very
      truly yours,

    

    
      	
              RXELITE
                HOLDINGS, INC.

               

              By:  

              
                

              

              Name:  

              
                

              

              Title:  

              
                
 

            	 	
              INVESTOR
                REPRESENTATIVE

               

              By:  

              
                

              

              Name:  

              
                

              

              Title: 

              
                

              

            

    

     

    Schedule
      I

    

    OFFERING
      DOCUMENTS

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Schedule
      II

    

    The
      Escrow Agent is authorized to accept instructions signed or believed by the
      Escrow Agent to be signed by the following on behalf of RxElite Holdings, Inc.
      and [       ] (the “Investor
      Representative”).

     

    RXELITE
      HOLDINGS, INC.

    

    
      	
              Name

            	 	
              True
                Signature

               

              
                
 

              OR

              
                
 

            

    

     

    INVESTOR
      REPRESENTATIVE

    

    
      	
              Name

            	 	
              True
                Signature

               

              
                
 

              ORUnassociated Document

     

    STOCK
      PURCHASE AGREEMENT

    

    STOCK
      PURCHASE AGREEMENT (this “Agreement”),
      dated
      as of July 13, 2007, by and between (i) Southridge Technology Group, Inc.,
      a
      Delaware corporation (“Pubco”)
      that
      will acquire all of the issued and outstanding capital stock of RxElite Holdings
      Inc., a Delaware corporation (“RxElite”),
      and
      succeed to the business of RxElite as its sole line of business (on a combined,
      post-acquisition basis, Pubco and its subsidiary, RxElite, are collectively
      referred to as “Seller”)
      and
      (ii) International Capital Advisory Inc. (the “Buyer”).

     

    WITNESSETH:

    

    WHEREAS,
      Seller desires to sell to the Buyer warrants to purchase shares of Seller’s
      common stock (the “Securities”)
      in
      consideration of certain consulting services provided by the Buyer; and

     

    WHEREAS,
      Seller has agreed to effect the registration of the shares of Common Stock
      of
      Seller underlying the Warrants (the “Underlying
      Shares”)
      subject to and on the terms and conditions set forth in an amended and restated
      registration rights agreement substantially in the form of Exhibit
      B
      hereto
      (the “Registration
      Rights Agreement”
and
      together with this Agreement and the Warrants, the “Transaction
      Documents”).

     

    NOW,
      THEREFORE, in consideration of the mutual covenants and agreements hereinafter
      set forth herein and for good and valuable consideration, the receipt and
      sufficiency of which are hereby mutually acknowledged, the parties agree as
      follows:

     

    1. Sale
      and Purchase of the Warrants.

     

    1.1 Sale
      and Purchase.

     

    Subject
      to the terms and conditions of this Agreement, at the Closing (as defined in
      Section 2 hereof), Seller shall issue to the Buyer, and the Buyer shall purchase
      from Seller, the Warrants listed on Exhibit
      A
      hereto
      in consideration for certain consulting services provided by the Buyer (the
      “Consideration”).

    

    1.2 Consideration
      and Payment.

     

    (a) The
      Warrants to purchase shares of Pubco’s Common Stock (“Common
      Stock”)
      shall
      be exercisable for two years following the date Pubco amends its certificate
      of
      incorporation in order to, among other things, increase its authorized capital
      to allow for full exercise of all Warrants, at an exercise price US$6.62 or
      US$9.38 per share, as indicated on Exhibit
      A
      and
      shall be in the form of Exhibit
      C
      hereto.

     

    (b) Delivery
      of Agreement.
      Upon
      the execution of this Agreement, the Consideration for the Securities shall
      be
      deemed delivered by the Buyer upon execution, delivery and performance of the
      relevant provisions of the Consulting Agreement attached as Exhibit
      D
      hereto.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    2. Closing.
      The
      closing of the sale and purchase of the Securities hereunder (the “Closing”)
      shall
      be deemed to take place at the offices of Seller, at 4:00 p.m., local time,
      on
      the date hereof or at such later time or date as the Buyer and Seller may
      mutually agree in writing. The date upon which the Closing shall occur is herein
      called the “Closing
      Date”.

     

    3. Representations
      and Warranties of Buyer.
      The
      Buyer hereby represents and warrants to Seller as follows:

     

    3.1 Due
      Existence; Authority.
      If the
      Buyer is a company, it is a duly organized legal entity, validly existing and
      in
      good standing under the laws of the state of its organization and has the
      requisite company power and authority to execute and deliver this Agreement
      and
      to perform its obligations hereunder. If the Buyer is a partnership, syndicate
      or other form of unincorporated organization, the Buyer has the necessary legal
      capacity and authority to execute and deliver this Agreement and to observe
      and
      perform its covenants and obligations hereunder and has obtained all necessary
      approvals in respect thereof. If the Buyer is a natural person, the Buyer has
      obtained the age of majority and has the legal capacity and competence to
      execute this Agreement and to take all actions required pursuant
      thereto.

     

    3.2 Enforceability.
      This
      Agreement has been duly executed and delivered by Buyer and is the valid and
      binding obligation of the Buyer, enforceable against the Buyer in accordance
      with its terms, except as such enforceability may be limited by bankruptcy,
      moratorium, insolvency, reorganization or other similar laws generally affecting
      the enforcement of creditors' rights, specific performance, injunctive or other
      equitable remedies.

     

    3.3 Investment
      Representations.
      The
      Buyer is acquiring the Securities, and any capital stock issuable upon exercise
      of the Securities, for the Buyer’s own account, for investment and not with a
      view to, or for sale in connection with, any distribution of such securities
      or
      any part thereof. The Buyer (i) has such knowledge and experience in financial
      and business affairs that it is capable of evaluating the merits and risks
      involved in purchasing the Securities, (ii) is able to bear the economic risks
      (including, a complete loss) involved in purchasing the Securities and has
      the
      adequate means of providing for its current needs and contingencies, (iii)
      has
      had the opportunity to ask questions of, and receive answers from, Seller and
      persons acting on Seller’s behalf concerning Seller’s business, management, and
      financial affairs and the terms and conditions of the Securities. The Buyer’s
      jurisdiction of residence is set forth on the signature page hereto.

     

    3.4 1933
      SEC Act.
      The
      Buyer acknowledges that (i) it has received and had the opportunity to review
      the draft of a Current Report on Form 8-K containing such information about
      RxElite as would be required to be disclosed in a Registration Statement on
      Form
      10-SB and accompanying Capitalization Table (the “Jumbo
      8-K”),
      attached as Exhibit
      E,
      with
      respect to the pending acquisition of RxElite by Pubco describing Seller’s
      business and operations following such acquisition, and (ii) it has reviewed
      the
      Jumbo 8-K, including, without limitation, the description of business and risk
      factors with respect to Seller and this offering set forth in the Jumbo 8-K.
      The
      Buyer acknowledges that all documents, records and books pertaining to this
      investment have been made available for inspection by the Buyer, the Buyer’s
      attorney and/or the Buyer’s accountant as set forth in Rule 502 of Regulation D
      under the Act and that all records and books of RxElite were available during
      reasonable business hours at RxElite’s principal place of business. The Buyer
      and/or its adviser(s) have had a reasonable opportunity to ask questions of
      and
      receive answers from RxElite, or a person or persons acting on its behalf,
      concerning the terms and conditions of the offering of the Securities, and
      to
      obtain additional information, to the extent possessed or obtainable without
      unreasonable effort or expense. All such questions have been answered to the
      full satisfaction of the Buyer. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    3.5 Accredited
      Investor; Residence.
      The
      Buyer is an “accredited investor” as such term is defined in Rule 501 of
      Regulation D under the Act. The jurisdiction referred to under “Address” in the
      signature page attached hereto is the Buyer’s residence or place of business and
      is not created or used solely for the purpose of acquiring the Securities and
      the Buyer is not purchasing the Securities for the account or benefit of any
      person in any jurisdiction other than such jurisdiction;

     

    3.6 THE
      BUYER RECOGNIZES THAT AN INVESTMENT IN SELLER IS SPECULATIVE AND INVOLVES A
      HIGH
      DEGREE OF RISK, AND THAT PURCHASERS OF SECURITIES COULD LOSE THEIR ENTIRE
      INVESTMENT.

     

    3.7 Certain
      Securities Matters.
      In
      reliance upon the Buyer’s representations and warranties in this Agreement
      (including Appendix
      A
      to this
      Agreement), neither the offering nor the sale of the Securities has been
      registered under the Act or any state securities laws or regulations. The Buyer
      was not offered or sold the Securities, directly or indirectly, by means of
      any
      form of general solicitation or general advertising, including the following:
      (i) any advertisement, article, notice, or other communication published in
      any
      newspaper, magazine, or similar medium or broadcast over television or radio;
      or
      (ii) to the knowledge of the Buyer, any seminar or meeting whose attendees
      had
      been invited by any general advertising. There is no public market for the
      Securities and Seller is under no obligation to register the Securities on
      the
      Buyer’s behalf or to assist the Buyer in complying with any exemption from
      registration (other than as set forth in the Registration Rights Agreement).
      The
      Buyer has not received or been provided with a prospectus, offering memorandum
      or sales or advertising literature and the Buyer’s decision to purchase the
      Securities was not based upon and the Buyer has not relied upon any verbal
      or
      written representations as to fact made by Seller or any other person (other
      than those representations and warranties set forth in Article 3 of this
      Agreement) but that the Buyer’s decision was based upon the information about
      Seller that is publicly available.

     

    3.8 Liquidity.
      The
      Buyer must hold the Securities indefinitely unless the sale or transfer thereof
      is subsequently registered under the Act or an exemption from such registration
      is available. The Buyer may not subsequently sell, assign, pledge, or otherwise
      transfer the Securities except: (i) pursuant to an effective registration
      statement registering the securities under the Act and/or applicable state
      securities laws, or (ii) pursuant to the opinion of counsel, which is
      satisfactory to Seller, that such registration under the Act and/or such state
      securities laws is not required to effect such subsequent sale, assignment,
      pledge, or other transfer. 

     

    3.9 Legend.
      The
      following legend referring to the foregoing restrictions will be set forth
      on
      certificates representing the Securities, as set forth below:

     

    THE
      SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
      A
      VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE
      OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
      RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
      THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF
      1933.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    3.10 Certain
      Prohibited Persons.
      The
      Buyer is not a person or entity (a “Person”)
      with
      whom a United States citizen, entity organized under the laws of the United
      States or its territories or entity having its principal place of business
      within the United States or any of its territories (collectively, a
“U.S.
      Person”)
      is
      prohibited from transacting business of the type contemplated by this Agreement,
      whether such prohibition arises under United States law, regulation, executive
      orders and lists published by the Office of Foreign Assets Control, Department
      of the Treasury (“OFAC”)
      (including those executive orders and lists published by OFAC with respect
      to
      Persons that have been designated by executive order or by the sanction
      regulations of OFAC as Persons with whom U.S. Persons may not transact business
      or must limit their interactions to types approved by OFAC (“Specially
      Designated Nationals and Blocked Persons”)
      or
      otherwise. Neither the Buyer nor any Person who owns an interest in the Buyer
      (collectively, a “Purchaser
      Party”)
      is a
      Person with whom a U.S. Person, including a United States Financial Institution
      as defined in 31 U.S.C. Section 5312, as amended (“Financial
      Institution”),
      is
      prohibited from transacting business of the type contemplated by this Agreement,
      whether such prohibition arises under United States law, regulation, executive
      orders and lists published by the OFAC (including those executive orders and
      lists published by OFAC with respect to Specially Designated Nationals and
      Blocked Persons) or otherwise.

     

    3.11 Certain
      Legislation.
      To the
      best of the Buyer’s knowledge, neither the Buyer nor any Purchaser Party, nor
      any Person providing funds to the Buyer: (i) is under investigation by any
      governmental authority for, or has been charged with, or convicted of, money
      laundering, drug trafficking, terrorist related activities, any crimes which
      in
      the United States would be predicate crimes to money laundering, or any
      violation of any Anti-Money Laundering Laws (as hereinafter defined); (ii)
      has
      been assessed civil or criminal penalties under any Anti-Money Laundering Laws;
      or (iii) has had any of its funds seized or forfeited in any action under any
      Anti-Money Laundering Laws. For purposes of this Section,
      the
      term “Anti-Money
      Laundering Laws”
shall
      mean laws, regulations and sanctions, state and federal, criminal and civil,
      that: (i) limit the use of and/or seek the forfeiture of proceeds from illegal
      transactions; (ii) limit commercial transactions with designated countries
      or
      individuals believed to be terrorists, narcotics dealers or otherwise engaged
      in
      activities contrary to the interests of the United States; (iii) require
      identification and documentation of the parties with whom a Financial
      Institution conducts business; or (iv) are designed to disrupt the flow of
      funds
      to terrorist organizations. Such laws, regulations and sanctions shall be deemed
      to include the USA Patriot Act of 2001, Pub. L. No. 107-56 (the “Patriot
      Act”),
      the
      Bank Secrecy Act, 31 U.S.C. Section 5311 et. seq. (the “Bank
      Secrecy Act”),
      the
      Trading with the Enemy Act, 50 U.S.C. Appendix, the International Emergency
      Economic Powers Act, 50 U.S.C. Section 1701 et. seq., and the sanction
      regulations promulgated pursuant thereto by the OFAC, as well as laws relating
      to prevention and detection of money laundering in 18 U.S.C. Sections 1956
      and
      1957.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    3.12 Bank
      Act.
      The
      Buyer is in compliance with any and all applicable provisions of the Patriot
      Act
      including, without limitation, amendments to the Bank Secrecy Act. If the Buyer
      is a Financial Institution, it has established and is in compliance with all
      procedures required by the Buyer and the Bank Secrecy Act.

     

    3.13 Appendix.
      The
      Buyer has accurately and truthfully completed Appendix
      A
      attached
      hereto.

     

    3.14 Covenants
      of Purchasers Not to Short Stock.
      The
      Buyer, on behalf of itself and its affiliates, hereby covenants and agree not
      to, directly or indirectly, offer to “short sell”, contract to “short sell” or
      otherwise “short sell” the securities of Seller, including, without limitation,
      the Securities.

     

    3.15 Restrictions
      in The People’s Republic of China.
      This
      Agreement and any offering materials may not be circulated or distributed in
      The
      People’s Republic of China (“PRC”)
      and
      the securities may not be offered or sold directly or indirectly to any resident
      of the PRC, or offered or sold to any person for re-offering or re-sale directly
      or indirectly to any resident of the PRC except pursuant to the applicable
      laws
      and regulations of the PRC.

     

    4. Further
      Assurances.
      Each of
      the parties shall, prior to or at the Closing, as may be appropriate, execute
      such documents and other papers and take such other further actions as may
      be
      reasonably required to carry out the provisions hereof and effectuate the
      transactions contemplated hereby. Each party shall use its commercially
      reasonable efforts to fulfill or obtain the fulfillment of the conditions to
      its
      obligation to effect the Closing, including promptly obtaining any consents
      required in connection herewith.

     

    5. Conditions
      Precedent to the Obligation of Buyer to Close.
      The
      obligation of the Buyer to complete the Closing, and the right for Seller to
      accept any purchase of Securities hereunder, is subject to the fulfillment
      on or
      prior to the Closing Date of all of the following conditions, any one or more
      of
      which may be waived by the holders of a majority of the Securities sold
      hereunder, collectively, in writing:

     

    5.1 Registration
      Rights Agreement.
      Seller
      shall have duly executed and delivered to the Buyer the Registration Rights
      Agreement.

     

    5.2 Jumbo
      8-K.
      RxElite
      shall have provided the Buyer with a substantially completed Jumbo
      8-K.

     

    5.3 Pubco
      Merger.
      Pubco
      shall have consummated its acquisition of RxElite’s issued and outstanding
      capital stock and Pubco shall have succeeded to RxElite’s business as its sole
      line of business.

     

    6. Conditions
      Precedent to the Obligation of Seller to Close.
      The
      obligation of Seller to complete the Closing is subject to the fulfillment
      on or
      prior to the Closing Date of all of the following conditions, any one or more
      of
      which may be waived by Seller in writing:

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    6.1 Agreements
      and Conditions.
      On or
      before the Closing Date, the Buyer shall have complied with and performed and
      satisfied in all material respects all agreements and conditions to be complied
      with and performed by such date pursuant to this Agreement.

     

    6.2 Execution
      and Delivery of Agreement.
      The
      Buyer shall have executed and delivered to Seller the Consulting Agreement
      attached as Exhibit
      D.

     

    6.3 Appendix.
      The
      Buyer shall have completed and delivered to Seller Appendix A
      to this
      Agreement, which shall be acceptable to Seller, in Seller’s
      discretion.

     

    6.4 Registration
      Rights Agreement.
      The
      Buyer shall have duly executed and delivered to Seller the Registration Rights
      Agreement.

     

    6.5 Jumbo
      8-K.
      RxElite
      shall have provided the Buyer with the Jumbo 8-K.

     

    6.6 Pubco
      Merger.
      Pubco
      shall have consummated its acquisition of RxElite’s issued and outstanding
      capital stock and Pubco shall have succeeded to RxElite’s business as its sole
      line of business.

     

    7. Miscellaneous.

     

    7.1 Notices.
      All
      notices and other communications hereunder shall be in writing and shall be
      deemed to have been given when delivered by hand or by facsimile transmission,
      when telexed, or upon receipt when mailed by registered or certified mail
      (return receipt requested), postage prepaid, to the parties at the following
      addresses (or at such other address for a party as shall be specified by like
      notice):

     

    (i) If
      to
      Seller:

    

    RxElite
      Holdings Inc.

    1404
      N.
      Main St., Ste. 200

    Meridian,
      ID 83642

    Attention:
      Daniel Chen, CEO

    Facsimile:
      (208) 288-1191

    

    With
      a
      copy (which copy shall not constitute notice) to:

    

    Morrison
      Foerster

    12531
      High Bluff Drive, Suite 100

    San
      Diego, California 92130

    Attention:
      Jay de Groot

    Facsimile:
      (858) 720-5125

    

    (ii) If
      to the
      Buyer: to the address listed on the signature page hereto.

    

    7.2 Entire
      Agreement; Exercise of Rights.
      

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (a) This
      Agreement (including the Appendices and Exhibits hereto) embodies the entire
      agreement and understanding of the parties hereto with respect to the subject
      matter hereof. No amendment or waiver of any provision of this Agreement, or
      consent to the departure by any party from any such provision, shall be
      effective unless it is in writing and signed by Seller and the holders of a
      majority of the Securities sold hereunder. Any such waiver or consent shall
      be
      effective only in the specific instance and for the specific purpose for which
      given.

     

    (b) No
      failure on the part of a party to exercise, and no delay in exercising, any
      right under this Agreement, or any agreement contemplated hereby, shall operate
      as a waiver hereof by such party, nor shall any single or partial exercise
      of
      any right under this Agreement, or any agreement contemplated hereby, preclude
      any other or further exercise thereof or the exercise of any other right.

     

    7.3 Governing
      Law.
      All
      questions concerning the construction, validity, enforcement and interpretation
      of this Agreement shall be governed by and construed and enforced in accordance
      with the internal laws of the State of New York, without regard to the
      principles of conflicts of law thereof. Each party agrees that all legal
      proceedings concerning the interpretations, enforcement and defense of the
      transactions contemplated by this Agreement (whether brought against a party
      hereto or its respective affiliates, directors, officers, shareholders,
      employees or agents) shall be commenced exclusively in the state and federal
      courts sitting in the County of New York, State of New York. Each party hereto
      hereby irrevocably submits to the exclusive jurisdiction of the state and
      federal courts sitting in the County of New York, State of New York for the
      adjudication of any dispute hereunder or in connection herewith or with any
      transaction contemplated hereby or discussed herein (including with respect
      to
      the enforcement of this Agreement), and hereby irrevocably waives, and agrees
      not to assert in any suit, action or proceeding, any claim that it is not
      personally subject to the jurisdiction of any such court. Each party hereto
      hereby irrevocably waives personal service of process and consents to process
      being served in any such suit, action or proceeding by delivering a copy thereof
      via overnight delivery (with evidence of delivery) to such party at the address
      in effect for notices to it under this Agreement and agrees that such service
      shall constitute good and sufficient service of process and notice thereof.
      Nothing contained herein shall be deemed to limit in any way any right to serve
      process in any manner permitted by law. Each party hereto hereby irrevocably
      waives, to the fullest extent permitted by applicable law, any and all right
      to
      trial by jury in any legal proceeding arising out of or relating to this
      Agreement or the transactions contemplated hereby. If either party shall
      commence an action or proceeding to enforce any provisions of this Agreement,
      then the prevailing party in such action or proceeding shall be reimbursed
      by
      the other party for its attorneys fees and other costs and expenses incurred
      with the investigation, preparation and prosecution of such action or
      proceeding. 

     

    7.4 Expenses.
      Seller
      and the Buyer shall, bear their respective expenses incurred in connection
      with
      the negotiation, preparation, execution and performance of this Agreement and
      the consummation of the transactions contemplated hereby, including, without
      limitation, all fees and expenses of agents, representatives, counsel, brokers
      or finders, and accountants.

     

    7.5 Acknowledgment;
      Waiver of Conflicts.
      The
      Buyer
      acknowledges that: (a) it has read this Agreement; (b) it has been represented
      in the preparation, negotiation and execution of this Agreement by legal counsel
      of its own choice or has voluntarily declined to seek such counsel; and (c)
      it
      understands the terms and consequences of this Agreement and is fully aware
      of
      the legal and binding effect of this Agreement. The Buyer understands that
      RxElite has been represented in the preparation, negotiation and execution
      of
      this Agreement by Morrison & Foerster LLP, counsel to RxElite, and that
      Morrison & Foerster LLP has not represented any Buyer or any stockholder,
      director or employee of Seller or any Investor in the preparation, negotiation
      and execution of this Agreement. Each of the Buyer and Seller acknowledges
      that
      Morrison & Foerster LLP has in the past represented and is now or may in the
      future represent the Buyer or its affiliates in matters unrelated to the
      transactions contemplated by this Agreement, including the representation of
      the
      Buyer or its affiliates in matters of a nature similar to those contemplated
      by
      this Agreement. Each of the Buyer and Seller hereby acknowledges that it has
      had
      an opportunity to ask for and has obtained information relevant to such
      representation, including disclosure of the reasonably foreseeable adverse
      consequences of such representation, and hereby waives any conflict arising
      out
      of such representation with respect to the matters contemplated by this
      Agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    7.6 Stock
      Dividend.
      As soon
      as practicable following the Closing, Pubco shall declare a stock dividend
      of
      10.036789 shares for each outstanding share of Common Stock (the “Dividend”),
      such
      that following consummation of the Dividend, the adjusted exercise price of
      each
      Warrant shall be $0.60 or $0.85 per share, as indicated on Exhibit
      A,
      and the
      adjusted number of shares of Common Stock issuable pursuant to the Warrants
      shall be 2,500,000 and 1,250,000 as indicated on Exhibit
      A.

     

    7.7 Limitations
      on Registration Rights.
      Notwithstanding any other provision of Section 2 of the Registration Rights
      Agreement, if Seller determines that it is desirable in order to comply with
      the
      requirements of the Securities and Exchange Commission that the number of
      securities to be registered in a registration statement filed pursuant to the
      Registration Rights Agreement be reduced, the Buyer hereby acknowledges and
      agrees that the Registrable Securities (as that term is defined in the
      Registration Rights Agreement) held by the Buyer that would otherwise be
      registered pursuant to the Registration Rights Agreement shall not be included
      on a registration statement until the Holders (as that term is defined in the
      Registration Rights Agreement) of Registrable Securities sold in consideration
      for (i) cash, or (ii) the conversion of certain Convertible Debentures
      originally issued in 2006 have been included in a registration statement filed
      pursuant to the Registration Rights Agreement. 

     

    [SIGNATURE
      PAGE FOLLOWS]

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the parties hereto have executed this Agreement on the date
      first above written.

     

    
      	 	
              Seller:

               

               

               

              By: 
                /s/ Daniel Chen           

              Name:
                Daniel Chen            

              Title:
                Chief Executive Officer          
                

               

            
	 	
               

               

              Buyer:
                International Capital Advisory, Inc.

               

              By:
                /s/ Morrie Tobin            

              Name:
                Morrie Tobin            

              Title:
                Vice President            

               

               

               

              Address
                ____________________________ 

                         
                _________________________

               

              Facsimile:
                ___________________________

               

            

    

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    APPENDIX
      A

    

    THIS
      APPENDIX MUST BE COMPLETED BY THE BUYER THAT IS RESIDENT IN THE UNITED STATES
      OF
      AMERICA

    

    

    NAME
      OF BUYER:
      _____________________

    

    I. PLEASE
      INITIAL THE SPACE AFTER THE DEFINITION OF “ACCREDITED INVESTOR” THAT APPLIES TO
      YOU. (ONLY ONE SPACE NEEDS TO BE INITIALED.)

    

    (i) Any
      natural person whose individual net worth, or joint net worth with that person’s
      spouse, at the time of his purchase exceeds $1,000,000. __________

     

    (For
      purposes of calculating an investor’s net worth, “net worth” is defined as the
      difference between total assets and total liabilities, including home, home
      furnishings, and personal automobiles.) 

    

    (ii) Any
      natural person who had an individual income in excess of $200,000 in each of
      the
      two most recent years or joint income with that person’s spouse in excess of
      $300,000 in each of those years and has a reasonable expectation of reaching
      the
      same income level in the current year. __________

     

    (iii) Any
      entity in which all of the equity owners are accredited investors.
      __________

     

    II. Please
      indicate the form of ownership desired for the Securities:

    

    _______
      Individual (one signature required)

    

    _______
      Joint Tenants with right of survivorship (both parties must sign)

    

    _______
      Tenants by the Entirety (both parties must sign)

    

    _______
      Tenants in Common (all parties must sign)

    

    _______
      Limited Liability Company (signature of authorized party or parties
      required)

    

    

    III.
      _____________________________________________________________________________

    Please
      PRINT here the exact name Buyer desires for registration of the
      Securities.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    
      	
              #
                Shares of Common Stock Underlying Warrant Pre-Dividend

            	
               

            	
              Exercise
                Price Pre-Dividend

            	
               

            	
              #
                Shares of Common Stock Underlying Warrant Post-Dividend

            	
               

            	
              Exercise
                Price Post-Dividend

            
	
               

              226,515

            	 	
               

              $6.26

            	 	
               

              2,500,000

            	 	
               

              $0.60

            
	
               

              113,257

            	 	
               

              $9.38

            	 	
               

              1,250,000

            	 	
               

              $0.85

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      B

    

    REGISTRATION
      RIGHTS AGREEMENT

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      C

    

    FORM
      OF
      WARRANT

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      D

    

    CONSULTING
      AGREEMENT

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    AMENDED
      AND RESTATED

    ADVISORY
      CONSULTING AGREEMENT

    

    Dated
      as of July 13, 2007

    

    This
      Amended and Restated Advisory Consulting Agreement (this “Agreement”)
      amends
      and restates the prior Advisory Consulting Agreement, dated as of September
      18,
      2006, by and between in its entirety RxElite (“RxElite”
or
      the
“Company”)
      and
      International Capital Advisory Inc. (“ICA”).

    

    
      	 	
              1.

            	
              Scope
                of Agreement: 

            

    

    

    During
      the term hereof, ICA will undertake certain Advisory Services on behalf of
      the
      Company, including:

    

    
      	 	
              (a)

            	
              Structuring
                and negotiating a potential merger and acquisition transaction involving
                the Company and a target public entity to be identified by ICA, in
                which
                the Company would be merged with and into the public entity (the
                “Merger
                Transaction”),
                with the surviving entity to continue the business of the Company.
                Any
                Merger Transaction shall be subject to the Company’s approval (at the
                Company’s sole discretion).

            

    

    

    
      	 	
              (b)

            	
              Advising
                in connection with the placement of equity financing of up to $15
                million
                US for the Company, with the express purpose of going public (the
                “Equity
                Funding”).
                Any financing shall be subject to the Company’s approval (at the Company’s
                sole discretion).

            

    

     

    
      	 	
              (c)

            	
              ICA
                shall aid RxElite in developing a capital market strategy and introduce
                RxElite to investment dealers, analysts, corporate finance
                representatives, institutional investors and retail brokers throughout
                North America, when appropriate. ICA shall work with the Company’s US
                Investor Relations firm and RxElite’s internal investor relations
                department on a regular basis to develop a long-term North American
                program to enhance RxElite’s presence in the capital markets. This will
                include setting up road shows and dealer presentations throughout
                North
                America and Europe.

            

    

    

    
      	 	
              (d)

            	
              ICA
                shall aid RxElite in identifying potential acquisition targets in
                Canada,
                the US and Europe. As part of a potential M&A transaction, ICA may
                introduce RxElite to parties who can facilitate a possible M&A
                financing. ICA will be required to seek RxElite’s approval before
                approaching any companies or financing sources, and any companies
                agreed
                upon must be listed in Attachment A.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	
              (e)

            	
              ICA
                shall aid RxElite in sourcing, negotiating and/or facilitating possible
                joint-ventures with pharmaceutical companies and medical device companies
                to enhance its distribution capabilities, product pipeline or licensing
                initiatives. ICA will be required to seek RxElite’s approval before
                approaching any companies, and any companies agreed upon must be
                listed in
                Attachment A.

            

    

     

    In
      performing such Advisory Services, ICA will exercise reasonable care in
      accordance with the standards of the investment banking
      profession.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    2. Fees
      Structure:

    

    The
      following outlines the fees structure:

     

    
      	 	
              (a)

            	
              In
                connection with the $15 million Equity Funding and the Merger Transaction,
                ICA shall be paid 

            

    

     

    
      	 	
              (i)

            	
              a
                cash consulting fee in the amount of $1,500,000 (“Cash Consulting Fee”),
                and 

            

    

     

    
      	 	
              (ii)

            	
              ICA
                will also be issued two Warrants:

            

    

     

    
      	 	
              (x)

            	
              a
                Warrant to acquire 226,515 shares (2,500,000 shares following the
                11.036789 for 1 forward stock split) of Common Stock of Southridge
                Technology Group, Inc. (“STG”),
                exercisable at $6.62 per share ($0.60 per share following the 11.036789
                for 1 forward stock split); and

            

    

     

    
      	 	
              (y)

            	
              a
                Warrant to acquire 113,257 shares (1,250,000 shares following the
                11.036789 for 1 forward stock split) of Common Stock of STG, exercisable
                at $9.38 per share ($0.85 per share following the 11.036789 for 1
                forward
                stock split).

            

    

     

    The
      exact
      amount of the Cash Consulting Fee and the exact number of Warrants shall be
      subject to final adjustment, as agreed to by the Company and ICA, in good faith,
      and shall be based on the time and efforts expended by ICA and the success
      of
      the $15 million Equity Funding and the Merger Transaction. 

     

    The
      payment of the Cash Consulting Fee will occur at such times as may be mutually
      agreed by the Company and ICA. 

     

    To
      the
      extent permitted by law and to the extent that the Company’s legal advisors
      advise the Company that the Company may register the Warrants without reducing
      the number of securities that may be registered by cash purchasers in the $15
      million Equity Funding, the Company shall include the Warrant in the
      registration statement relating to the securities of cash purchasers in the
      $15
      million Equity Funding. 

     

    ICA
      hereby acknowledges and agrees that the tender of the Warrants to ICA shall
      occur only after (and is in all respects subject to and conditioned upon) the
      completion of the acquisition by STG of the Company’s issued and outstanding
      capital stock and succession by STG of the Company’s business as its sole line
      of business as provided in the Securities Purchase Agreement of even date
      herewith.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ICA
      acknowledges and agrees that the Warrant will be in the form of the Warrants
      delivered to purchasers in the Equity Financing, provided, however, that the
      exercise price of some of the Warrants will be $6.62
      (in lieu
      of $9.38),
      as
      described above.

     

    
      	 	
              (b)

            	
              The
                Company will pay ICA a monthly consulting fee of $10,000 for 12 months
                with the first payment due upon full execution of this
                Agreement. Additionally,
                once the first 12 month period described herein is completed, RxElite
                will
                pay ICA a monthly retainer of US $12,500 for the subsequent twelve
                month
                period. All payments are due and payable on the first day of each
                month.

            

    

    

    
      	 	
              (c)

            	
              if
                a merger or acquisition is completed or a funding related to a merger
                or
                acquisition is completed with any company or entity introduced directly
                by
                ICA (not including the Reverse Take-Over Merger), then RxElite pays
                a work
                fee to ICA in an amount equal to the greater of 6% of the total value
                of
                the transaction or US $150,000. ICA will be required to seek RxElite’s
                approval before approaching any companies, and any merger or acquisition
                candidate companies agreed upon must be listed in Attachment
                A.

            

    

    

    
      	
            	(d)	
              if
                a strategic or partnership agreement, including without limitation,
                a
                distribution, marketing, licensing, product or manufacturing agreement,
                is
                entered into or from an ICA Prospect, the transaction fee to be paid
                to
                ICA shall be an upfront payment and commission equal to the following
                percentage of "gross revenues", as defined below, of all products
                or
                services sold to, or through, RxElite or the ICA Prospect, in any
                market
                addressed by the business
                relationship:

            

    

    

    ●
      up-front
      one-time payment equal to US $35,000.00 per product;

    ●
      Year
      1: 1% of gross revenues      ●
      Year
      2: 2% of gross revenues

    ●
      Year
      3: 3% of gross revenues     Year 4: 3% of gross
      revenues

                Year
      5: 3% of gross
      revenues

     

    For
      the
      purpose of this provision, a "year" shall commence on the date of the first
      sale
      of a product/service under the distribution, marketing, manufacturing or
      licensing agreement and each anniversary date thereafter. ICA
      will
      be required to seek RxElite’s approval before approaching any strategic or
      partnership agreement, including without limitation, a distribution, marketing,
      licensing, product or manufacturing agreement or related companies, and any
      ICA
      Prospect companies agreed upon must be listed in Attachment A.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        	
              	(e)	
                All
                  air, hotel, meal, gas, and parking expenses and all other reasonable
                  expenses relating to RxElite activities, submitted on a monthly
                  basis. Any
                  trip must be pre-approved by RxElite. Office and office expenses
                  shall be
                  paid as a flat fee of $300 monthly during the term of the
                  agreement.

              

      

    

     

    
      	 	
              3.

            	
              Confidentiality:

            

    

    

    The
      Company and ICA agree to hold confidential the terms and conditions of this
      Agreement except as required by applicable law including, without limitation,
      the rules and regulations of the Securities and Exchange Commission. Each party
      hereby consents to the granting of an injunction against it by any court of
      competent jurisdiction to enjoin it from violating the foregoing confidentiality
      provisions. Each party hereby agrees that the other will not have an adequate
      remedy at law in the event of a breach of the confidentiality provisions
      contained herein, and such party will suffer irreparable damage and injury
      as a
      result of any such breach. Resort to such equitable relief shall not, however,
      be construed to be a waiver of any other rights or remedies which such party
      may
      have

     

    4.
      Term: 

    

    
      	 	
              (a)

            	
              This
                Agreement shall be for a minimum period of 24 months commencing on
                the
                effective date of this Agreement, and renewable in writing thereafter
                on a
                month to month basis or such other time period as mutually agreed
                to by
                the parties. This agreement may be terminated by either party in
                writing
                with 30 days notice, but no sooner than the 24th
                month of the agreement.

            

    

    

    
      	 	
              (b)

            	
              In
                the event that a funding has not occurred by December 31, 2007, this
                agreement is automatically
                terminated.

            

    

    

    
      	 	
              (c)

            	
              Notwithstanding
                the termination of this Agreement, the provisions of Section 2(c)
                and 2(d)
                shall survive for twelve months following termination, and in the
                case of
                2(d), the Company shall make all payments due to ICA for the time
                periods
                and amounts as outlined in 2(d).

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    This
      agreement constitutes the entire agreement by the parties. Any previous written
      acknowledgement, statement or prior understanding whether in writing or
      discussed orally between the parties related to the agreement or the
      relationship between the parties (including, without limitation, the letter
      agreement dated as of September 18, 2006) is
      superseded by this agreement.

    

    Unless
      otherwise stated, all figures in this Agreement are stated in US dollars. Please
      confirm your agreement with the foregoing terms by signing this Agreement in
      the
      place provided below and returning two executed copies to the offices of ICA
      to
      the attention of Mr. Morrie Tobin.

    

    

    Yours
      very truly,

    

    On
      behalf
      of      

    INTERNATIONAL
      CAPITAL ADVISORY INC.   

    

    By:       

    

    

    _________________________________________

    Mr.
      Morrie Tobin   

    Vice-President      

    

    

    Acknowledged
      and agreed.

    

    On
      behalf
      of 

    

    

    RxElite
      Holdings Inc.  

    

    By:

    

    

    

    _________________________________________

    Mr.
      Daniel Chen, CEO

    Date:

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ATTACHMENT
      A

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    EXHIBIT
      E

    

    JUMBO
      8-K

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]